Adam V Patterson

12PUBLICATIONS
38CO-AUTHORS
Haematological tumoursNanophotonicsMolecular targetsWastewater treatment processesCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Nov 06, 2024
The third generation AKR1C3-activated prodrug, ACHM-025, eradicates disease in preclinical models of aggressive T-cell acute lymphoblastic leukemia.

Cara E Toscan, Hannah McCalmont, Amir Ashoorzadeh

|Jun 27, 2024
Structural Evaluation of a Nitroreductase Engineered for Improved Activation of the 5-Nitroimidazole PET Probe SN33623.

Abigail V Sharrock, Jeff S Mumm, Elsie M Williams

|Feb 26, 2022
Interrogation of the Structure-Activity Relationship of a Lipophilic Nitroaromatic Prodrug Series Designed for Cancer Gene Therapy Applications.

Amir Ashoorzadeh, Alexandra M Mowday, Christopher P Guise

|Dec 28, 2021
Restoring Tumour Selectivity of the Bioreductive Prodrug PR-104 by Developing an Analogue Resistant to Aerobic Metabolism by Human Aldo-Keto Reductase 1C3.

Maria R Abbattista, Amir Ashoorzadeh, Christopher P Guise

|Nov 27, 2021
Bioreductive prodrug PR-104 improves the tumour distribution and titre of the nitroreductase-armed oncolytic adenovirus ONYX-411NTR leading to therapeutic benefit.

Dean C Singleton, Alexandra M Mowday, Chris P Guise

|Oct 09, 2021
Selectively Targeting Tumor Hypoxia With the Hypoxia-Activated Prodrug CP-506.

Alexander M A van der Wiel, Victoria Jackson-Patel, Raymon Niemans

Pageof 2

Frequent Collaborators

9 joint publications

Jeff B Smaill

6 joint publications

Alexandra M Mowday

4 joint publications

David F Ackerley

2 joint publications

Amir Ashoorzadeh